Bo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Li has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Motooka
Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2 shared publications - Daisuke Okuzaki
Laboratory for Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, The University of Osaka, Suita 565-0871, Japan
2 shared publications - Hisako Kayama
Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871
2 shared publications - Kiyoshi Takeda
Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University , Suita, Osaka 565-0871
2 shared publications - Shinichiro Shinzaki
Department of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Japan
2 shared publications - Shota Nakamura
Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University
2 shared publications
Latest Publications
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadm6843
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation
Ulcerative colitis (UC) develops through a complicated interaction between the host and microbiota. Intestinal fibroblasts are believed to play crucial roles in the pathogenesis of UC, but the influence of the host-microbiota interaction on the pathophysiology of intestinal fibroblasts remains poorly understood. Here, we demonstrate that OTU deubiquitinase 3 (OTUD3) suppresses pathologic activation of fibroblasts exposed to microbial cyclic GMP-AMP (3′3’-cGAMP) in the colon by deubiquitinating stimulator of interferon genes (STING). Mice harboring a UC risk missense variant in the Otud3 gene showed pathological features of UC in the colon after transplantation of a fecal microbiota with the potential to produce excessive cGAMP from patients with UC. Collectively, these results highlight a mechanism of the interaction between OTUD3 in host fibroblasts and STING-activating microbiota in UC development.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadm6843
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation
Ulcerative colitis (UC) develops through a complicated interaction between the host and microbiota. Intestinal fibroblasts are believed to play crucial roles in the pathogenesis of UC, but the influence of the host-microbiota interaction on the pathophysiology of intestinal fibroblasts remains poorly understood. Here, we demonstrate that OTU deubiquitinase 3 (OTUD3) suppresses pathologic activation of fibroblasts exposed to microbial cyclic GMP-AMP (3′3’-cGAMP) in the colon by deubiquitinating stimulator of interferon genes (STING). Mice harboring a UC risk missense variant in the Otud3 gene showed pathological features of UC in the colon after transplantation of a fecal microbiota with the potential to produce excessive cGAMP from patients with UC. Collectively, these results highlight a mechanism of the interaction between OTUD3 in host fibroblasts and STING-activating microbiota in UC development.
- Open Access
- 24 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (7)
Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.
- 24 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (7)
Open AccessLysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.